Effect of NMN Supplementation on Organ System Biology

Not Applicable

Completed

• Conditions: Glucose Metabolism Disorders
• Interventions: Other: Placebo; Dietary Supplement: Treatment

• Registration Number: NCT04571008
• Lead Sponsor: Washington University School of Medicine

Brief Summary

The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

Detailed Description

This study is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.

Study Timeline

• Study First Submitted: 2020-09-24
• Study First Submitted QC: 2020-09-24
• Study First Posted: 2020-09-30
• Study Start: 2020-10-01
• Primary Completion: 2025-03-04
• Study Completion: 2025-03-04
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-15
• Last Update Posted: 2025-04-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• BMI 25.0-50.0 kg/m²
• Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.

Exclusion Criteria

• Women who are still having menses
• Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
• Persons who consume moderate-large amounts of caffeine daily (>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
• Unstable weight (>3% change during the last 2 months before entering the study)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	At least 16 weeks of placebo.
NMN supplementation	Treatment	At least 16 weeks of NMN.

Primary Outcome Measures

Name	Time	Method
Change in Muscle insulin sensitivity	before and after at least 16 weeks of treatment	The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period.

Secondary Outcome Measures

Name	Time	Method
Changes in glucose tolerance	before and after at least 16 weeks of treatment	The outcome will be assessed during modified oral glucose tolerance test

Trial Locations

Locations (1)

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States